These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17587386)

  • 1. PPARgamma agonists: safety issues in heart failure.
    Tang WH; Maroo A
    Diabetes Obes Metab; 2007 Jul; 9(4):447-54. PubMed ID: 17587386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
    Karalliedde J; Buckingham RE
    Drug Saf; 2007; 30(9):741-53. PubMed ID: 17722967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
    Kintscher U; Goebel M
    Curr Opin Investig Drugs; 2009 Apr; 10(4):381-7. PubMed ID: 19337960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
    Goltsman I; Khoury EE; Winaver J; Abassi Z
    Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
    Tanaka T
    Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones and PPARĪ³ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones and heart failure: a teleo-analysis.
    Singh S; Loke YK; Furberg CD
    Diabetes Care; 2007 Aug; 30(8):2148-53. PubMed ID: 17536074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones and congestive heart failure--exacerbation or new onset of left ventricular dysfunction?
    Srivastava PM; Calafiore P; MacIsaac RJ; Hare DL; Jerums G; Burrell LM
    Diabet Med; 2004 Aug; 21(8):945-50. PubMed ID: 15270804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
    Hollenberg NK
    Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
    Scheen AJ
    Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
    Granberry MC; Hawkins JB; Franks AM
    Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.